On May 8, 2008, Biogen
Idec filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the Company's 2008 Annual Meeting.
In accordance with a January 2002 settlement between the two companies, Biogen
will make a final $55 million payment to Berlex.
Idec's Board said it will review the notice and consider it in light of the best interests of all shareholders of the Company.
Idec also announced that lumiliximab was granted Fast Track and Orphan Drug designations by the U.
Bucknum joined Biogen
in 1996 after a 20 year career with DuPont and DuPont Merck Pharmaceuticals, where he served in diverse management roles in legal, government and public affairs, international, marketing, and regulatory affairs.
Galiximab represents a new approach with the potential to benefit patients with NHL," said David Parkinson, senior vice president, Oncology Research and Development, Biogen
remedies related to a dispute involving a 1989 agreement among Biogen
Idec (NASDAQ: BIIB) creates new standards of care in oncology, neurology and immunology.
The arbitration was instituted by SmithKline in 1993 and related to the rate of royalties SmithKline has paid Biogen
These studies have been initiated internationally, and Biogen
Idec plans to initiate these studies in the U.
is focused primarily on developing and testing products for the treatment of multiple sclerosis, cardiovascular disease, inflammatory diseases, and certain viruses and cancers.
Idec (NASDAQ: BIIB) and Syntonix Pharmaceuticals today announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen